Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.

Phase III long-term safety study of Effexor XR in patients with major depression.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Depression Behavior Behavioral Symptoms

Age range

20 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Nagoya, Aichi-ken, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816)

Exclusion criteria

Patients with schizophrenia or any other psychotic disorder
Patients with history or presence of bipolar disorder

Treatment and study plan

Effexor XR

Drug

Primary outcomes

Incidence of adverse events

Secondary outcomes

Quantitative data for laboratory data

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

Phase III Long-Term Administration Study of Effexor XR for the Treatment of Depression

Important dates

Study start: 2004
First posted: Sep 23, 2005
Registry last updated: May 24, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed